- Home
- PRPO vs SONN Comparison
PRPO vs SONN Comparison
Compare PRPO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- SONN
- Stock Information
- Founded
- PRPO N/A
- SONN N/A
- Country
- PRPO United States
- SONN United States
- Employees
- PRPO N/A
- SONN N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- SONN Health Care
- Exchange
- PRPO Nasdaq
- SONN Nasdaq
- Market Cap
- PRPO 22.0M
- SONN 24.2M
- IPO Year
- PRPO N/A
- SONN N/A
- Fundamental
- Price
- PRPO $15.41
- SONN $3.18
- Analyst Decision
- PRPO
- SONN Strong Buy
- Analyst Count
- PRPO 0
- SONN 1
- Target Price
- PRPO N/A
- SONN $20.00
- AVG Volume (30 Days)
- PRPO 10.3K
- SONN 642.3K
- Earning Date
- PRPO 08-13-2025
- SONN 08-13-2025
- Dividend Yield
- PRPO N/A
- SONN N/A
- EPS Growth
- PRPO N/A
- SONN N/A
- EPS
- PRPO N/A
- SONN N/A
- Revenue
- PRPO $21,242,000.00
- SONN $1,000,000.00
- Revenue This Year
- PRPO N/A
- SONN $5,376.22
- Revenue Next Year
- PRPO N/A
- SONN N/A
- P/E Ratio
- PRPO N/A
- SONN N/A
- Revenue Growth
- PRPO 27.05
- SONN 1689.52
- 52 Week Low
- PRPO $3.90
- SONN $1.08
- 52 Week High
- PRPO $16.89
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- PRPO 69.89
- SONN 44.82
- Support Level
- PRPO $14.04
- SONN $3.02
- Resistance Level
- PRPO $16.27
- SONN $3.80
- Average True Range (ATR)
- PRPO 0.64
- SONN 0.34
- MACD
- PRPO 0.10
- SONN -0.00
- Stochastic Oscillator
- PRPO 84.48
- SONN 15.00
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.